Superficial Dermatophytosis across the World’s Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising Challenges
ACS Omega · 05.09.2023 · 8 (35) · 31575-31599
DOI: 10.1021/acsomega.3c01988 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Omega, online erschienen am 22.08.2023. Verfasst von Puja Keshwania und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Mullana, Ambala, Haryana 133207, India. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Education - Kingdom of Saudi Arabi.
Abstract (Originalsprache)
The most prevalent infection in the world is dermatophytosis, which is a major issue with high recurrence and can affect the entire body including the skin, hair, and nails. The major goal of this Review is to acquire knowledge about cutting-edge approaches for treating dermatophytosis efficiently by adding antifungals to formulations based on nanocarriers in order to overcome the shortcomings of standard treatment methods. Updates on nanosystems and research developments on animal and clinical investigations are also presented. Along with the currently licensed formulations, the investigation also emphasizes novel therapies and existing therapeutic alternatives that can be used to control dermatophytosis. The Review also summarizes recent developments on the prevalence, management approaches, and disadvantages of standard dosage types. There are a number of therapeutic strategies for the treatment of dermatophytosis that have good clinical cure rates but also drawbacks such as antifungal drug resistance and unfavorable side effects. To improve therapeutic activity and get around the drawbacks of the traditional therapy approaches for dermatophytosis, efforts have been described in recent years to combine several antifungal drugs into new carriers. These formulations have been successful in providing improved antifungal activity, longer drug retention, improved effectiveness, higher skin penetration, and sustained drug release.
Autor:innen und Institutionen
- Department of Microbiology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Mullana, Ambala, Haryana 133207, India.
- University Institute of Pharmaceutical Sciences, UGC-Centre of Advanced Studies, Panjab University, Chandigarh 160014, India.
- Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj 11942, Saudi Arabia.
- Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21961, Saudi Arabia.
ORCID-Profile: Gajanand Sharma
Förderung
- Ministry of Education - Kingdom of Saudi Arabi
Zitieren
APA
Keshwania, P., Kaur, N., Chauhan, J., Sharma, G., Afzal, O., Alfawaz Altamimi, A. S., & Almalki, W. H. (2023). Superficial Dermatophytosis across the World’s Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising Challenges. ACS Omega, 8(35), 31575-31599. https://doi.org/10.1021/acsomega.3c01988
Vancouver
Keshwania P, Kaur N, Chauhan J, Sharma G, Afzal O, Alfawaz Altamimi AS, et al. Superficial Dermatophytosis across the World’s Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising Challenges. ACS Omega. 2023;8(35):31575-31599. doi:10.1021/acsomega.3c01988
BibTeX
@article{Keshwania2023,
author = {Keshwania, Puja and Kaur, Narinder and Chauhan, Jyoti and Sharma, Gajanand and Afzal, Obaid and Alfawaz Altamimi, Abdulmalik Saleh and Almalki, Waleed H},
title = {Superficial Dermatophytosis across the World’s Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising Challenges},
journal = {ACS Omega},
year = {2023},
volume = {8},
number = {35},
pages = {31575--31599},
doi = {10.1021/acsomega.3c01988}
}
EUVIMED